Prevention of rheumatic fever: a statement for health professionals by the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the young, the American Heart Association.
Dajani
A S
AS
Office of Scientific Affairs, American Heart Association, Dallas, TX 75231.
Bisno
A L
AL
Chung
K J
KJ
Durack
D T
DT
Gerber
M A
MA
Kaplan
E L
EL
Millard
H D
HD
Randolph
M F
MF
Shulman
S T
ST
Watanakunakorn
C
C
D000572:American Heart Association; D004334:Drug Administration Schedule; D004697:Endocarditis, Bacterial / Q000517:prevention & control; D006801:Humans; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use; D011322:Primary Prevention; D012213:Rheumatic Fever / Q000188:drug therapy / Q000517:prevention & control*; D013290:Streptococcal Infections / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D014481:United States
D010406:Penicillins